Wed, Dec 21, 2022
The 30-share BSE benchmark Sensex tumbled 635.05 points or 1.03 per cent to settle at 61,067.24. While the broader NSE Nifty declined 186.20 points or 1.01 per cent to end at 18,199.10.
More >
Tue, Mar 30, 2021
ICICI Securities remain positive on the pharmaceutical sector considering high possibility of growth revival in India formulations on low base of FY21, stable pricing in US generics and sustenance of cost control initiatives seen during FY21 due to pandemic, albeit partially over long term.
Thu, Jan 21, 2021
After four difficult years, the India pharma sector rallied in 2020, and HSBC expects the benign operating environment to lead to another good year. HSBC revised their estimates and target prices, and rolled forward our valuations to December 2022e from September 2022e. HSBC also preview Q3 FY21e results, where they expect the recovery to continue for most of the companies that HSBC covers.
Wed, Aug 14, 2019
Divi’s Laboratories (Divi’s) posted a softer-than-expected Q1FY20. Topline grew 17 percent year-on-year (YoY) on a tough base, but declined sequentially in what is a seasonally weak quarter, said Edelweiss.
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
